Aetion is a healthcare technology company that provides real-world evidence analytics for life sciences, payers, and regulators. Its platform analyzes real-world data to support safety, effectiveness, cost, and value decisions for medical products.
UpMarket does not offer Aetion shares. This page covers Aetion's history before the acquisition.
Aetion was acquired by Datavant in July 2025 and no longer has shares of its own. UpMarket does not offer Aetion shares. This page covers Aetion's valuation and funding history before the acquisition.
Aetion was acquired by Datavant in July 2025.
See how Aetion's private-market valuation changed across funding rounds before the acquisition.
See reported funding rounds and revenue figures on this page, with their sources.
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| May 2021 | Series C |
Warburg Pincus led Aetion’s $110 million Series C in 2021, with B Capital and Foresite Capital also participating. The New York-based real-world evidence company said it had raised $212 million total at that point.
Aetion Evidence Platform uses electronic health records, lab tests, and insurance claims to generate evidence on treatment safety, effectiveness, and value. Its customers include biopharma companies, payers, and regulatory agencies, widening integration depth across stakeholders.
Datavant announced an agreement to acquire Aetion on May 15, 2025, pairing a health data platform with a real-world evidence leader. The deal signals continued demand for RWE tools that support healthcare decision-making.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
Browse the directory →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. Aetion was acquired by Datavant in July 2025 and no longer has shares of its own. UpMarket does not offer Aetion shares.
Aetion has no stock price of its own since its acquisition by Datavant. The prices shown on this page are historical private-market prices from before the acquisition.
No. Aetion was acquired by Datavant and UpMarket does not offer Aetion shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Aetion is no longer an independent company, so its shares are not available to buy. This page is kept for its historical funding and valuation data. UpMarket does not offer Aetion shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Aetion was acquired by Datavant in July 2025. What former shareholders received, cash or shares of the buyer, was set by the terms of the acquisition.
UpMarket does not offer Aetion shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
Aetion's last valuation was set by its acquisition by Datavant. The figures on this page show its valuation history before the acquisition.
Aetion provides real-world evidence analytics for life sciences, payers, and regulators, generating $39.9M in 2024 revenue; it raised a $110M Series C to accelerate global growth. Aetion is now part of Datavant, and UpMarket does not offer its shares.